Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago‐gastric Diseases (PROCEED): A single‐arm phase 2 trial
The addition of pembrolizumab to neoadjuvant CRT followed by surgical resection was overall well-tolerated and resulted in numerically higher rates of pCR compared to historical controls. Further studies with optimized patient selection are warranted to validate the efficacy of this treatment paradigm.
Authors
- Hope E. Uronis (ORCID: https://orcid.org/0009-0000-1565-1939)
- John H. Strickler (ORCID: https://orcid.org/0000-0001-7579-1175)
- Christopher G. Willett (ORCID: https://orcid.org/0000-0002-4573-4302)
- Manisha Palta (ORCID: https://orcid.org/0000-0002-9085-9075)
- E. Duffy
- Brian G. Czito (ORCID: https://orcid.org/0000-0001-5074-767X)
- Donna Niedzwiecki (ORCID: https://orcid.org/0000-0002-3566-0450)
- Pooja Karukonda (ORCID: https://orcid.org/0000-0001-8358-3640)
- Thomas A. D’Amico
Institutions
- Duke Medical Center (US)
Publication Details
- Journal
- Cancer
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1002/cncr.70213
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00